ArticleBlood advances2026

Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

Toby A Eyre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.